X4 Pharmaceuticals, Inc
XFOR- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001501697
In the last 90 days, X4 Pharmaceuticals, Inc insiders filed 0 open-market purchases and 2 sales; 89 institutions reported holding it in 13F filings for Q2 2026, worth $463.0M in total; no superinvestor holds it.
Q4 2023 vs. Q3 2023
How the institutions holding X4 Pharmaceuticals, Inc changed between Q3 2023 and Q4 2023.
All holders in Q4 2023All holders in Q3 2023
| Measure | Q3 2023 | Of which not filed for Q4 2023 | Q4 2023 | Change |
|---|---|---|---|---|
| Holders | 91 | 1 | 93 | +3 |
| Shares | 112.4M | 12.6K | 96.8M | −15.6M (−13.9%) |
| Value | $122.6M | $13.8K | $81.2M | −$41.4M (−33.8%) |
1 institution that held it in Q3 2023 haven't filed for Q4 2023 yet. Not filing isn't selling, so the changes leave them out.
New holders (17)
Institutions that held X4 Pharmaceuticals, Inc at the end of Q4 2023 but not at the end of Q3 2023.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Propel Bio Management, LLC | 535,000 | $448.6K | 0.37% |
| Acadian Asset Management LLC | 181,609 | $152.0K | 0.00% |
| Virtu Financial LLC | 127,718 | $107.0K | 0.01% |
| Knott David M Jr | 119,300 | $100.0K | 0.04% |
| Amundi | 81,305 | $66.8K | 0.00% |
| XTX Topco Ltd | 69,086 | $57.9K | 0.01% |
| Squarepoint Ops LLC | 64,763 | $54.3K | 0.00% |
| Bayesian Capital Management, LP | 39,400 | $33.0K | 0.00% |
| State Board of Administration of Florida Retirement System | 31,979 | $26.8K | 0.00% |
| Walleye Capital LLC | 29,616 | $24.8K | 0.00% |
| HRT Financial LP | 17,084 | $14.0K | 0.00% |
| Pathstone Holdings, LLC | 12,637 | $10.6K | 0.00% |
| StoneX Group Inc. | 11,751 | $9.85K | 0.00% |
| Mission Wealth Management, LP | 10,000 | $8.38K | 0.00% |
| Lazari Capital Management, Inc. | 10,000 | $8.38K | 0.00% |
| ICA Group Wealth Management, LLC | 2,575 | $2.16K | 0.00% |
| Raelipskie Partnership | 1,000 | $839 | 0.00% |
Sold out (14)
Institutions that held X4 Pharmaceuticals, Inc at the end of Q3 2023 and filed for Q4 2023 without it.
| Institution | Shares, Q3 2023 | Value, Q3 2023 |
|---|---|---|
| Polar Capital Holdings Plc | 7,500,000 | $8.18M |
| Tri Locum Partners LP | 6,247,500 | $6.81M |
| Stonepine Capital Management, LLC | 5,273,685 | $5.75M |
| Monashee Investment Management LLC | 427,265 | $465.7K |
| Verition Fund Management LLC | 88,395 | $96.4K |
| MetLife Investment Management | 65,421 | $71.3K |
| Deutsche Bank AG | 61,227 | $66.7K |
| Manufacturers Life Insurance Company, The | 51,592 | $56.2K |
| Two Sigma Securities, LLC | 32,337 | $35.2K |
| Wolverine Trading, LLC | 14,746 | $16.1K |
| Marshall Wace, LLP | 12,890 | $14.1K |
| Total Clarity Wealth Management, Inc. | 11,532 | $12.6K |
| 1620 Investment Advisors, Inc. | 10,000 | $10.9K |
| Metropolitan Life Insurance Co | 6,779 | $7.39K |
Not filed for Q4 2023 yet (1)
Institutions that held X4 Pharmaceuticals, Inc at the end of Q3 2023 and haven't filed a 13F for Q4 2023. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q3 2023 | Value, Q3 2023 |
|---|---|---|
| Pathstone Family Office, LLC | 12,637 | $13.8K |